AstraZeneca was among the first multinational pharmaceutical firms to invest deeply in China's healthcare sector. Through ...

Topline results from the SAFFRON study are estimated to be reported in the first half of 2026, followed by submission of results for presentation at an appropriate medical congress. If favorable, the ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more ...

Eli Lilly and Novo Nordisk are expected to announce deals with the Trump administration to cut prices of their weight-loss drugs in exchange for Medicare coverage, a White House source told on Tuesday ...

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.